Clinical activity was evaluated in patients who had received the first dose of RMC-6236 at least eight weeks prior to the data extraction date (n=86). Among the 40 efficacy evaluable NSCLC patients, the objective response rate was 38 percent, with ...
in an ongoing phase I/Ib clinical trial (NCT05379985). RAS驱动型癌症占高达30%的人类癌症。RMC-6236是一种RAS(ON)多选择性非共价抑制剂,能够非共价地抑制活跃的GTP结合状态的突变型和野生型RAS同源异构体,具有广泛的治疗潜力,以满足医疗需求。RMC-6236在依赖RAS的细胞系中表现出强大的抗癌活性,特别是在KRAS...
“We are pleased to report encouraging clinical data for both RMC-6236 and RMC-6291, two pioneering RAS(ON) Inhibitors that are providing strong validation of our RAS(ON) Inhibitor platform broadly. The RMC-6236 safety data support that this highly innovative, oral RASMULTI Inhibitor is generall...
RMC-6236 can lead to meaningful clinical responses in patients at dose levels that are generally well tolerated,” said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. “These data also confirm that RMC-6236 can target multiple c...
而另外两款抑制剂中，RMC-6291的靶点为KRAS G12C，RMC-9805的靶点为KRAS G12D。”参考来源：1. https://doi.org/10.1016/j.annonc.2023.10.025 2. https://www.targetedonc.com/view/rmc-9805-hits-milestone-in-early-phase-clinical-trial-of-kras-g12d-solid-tumors ...
RMC-6236是一种新型的口服、非共价 RASMULTI(ON)抑制剂,它对典型 RAS 亚型的突变型和其它变体均具备活性、对 GTP 结合或分离状态都具有选择性。临床前研究表明,RMC-6236 可以持续、高强度抑制多种 RAS 突变肿瘤的生长,特别是存在 KRAS G12X(X = A、D、R、S 或 V)突变的胰腺癌和非小细胞肺癌。I 期临床...
--Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced encouraging preliminary clinical data for RMC-6236, its RAS MULTI Inhibitor, and RMC-6291, its RAS G12C Inhibitor, fro
我们现在正在研究三个高度创新的RAS抑制剂,且它们具有互补的特性——RMC-6236适用于由多种RAS突变引发的癌症患者,而另外两款抑制剂中,RMC-6291的靶点为KRAS G12C,RMC-9805的靶点为KRAS G12D。” 在这项1/1b临床研究中,研究人员将主要评估患者用药...
Preclinical studies with RMC-6236 demonstrated deep and sustained regressions across multiple RASMUT tumor types at well tolerated doses, particularly tumors harboring KRAS glycine-12 substitutions (KRASG12X).Methods: Patients with previously treated, advanced KRASG12X mutant solid tumors were enrolled ...
Thus, RAS(ON) multi-selective inhibitors can target multiple oncogenic and wild-type RAS isoforms and have the potential to treat a wide range of RAS-addicted cancers with high unmet clinical need. A related RAS(ON) multi-selective inhibitor, RMC-6236, is currently under clinical evaluation in...